Emergent BioSolutions Inc.
EBS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $231 | $141 | $222 | $195 |
| % Growth | 64% | -36.6% | 14.1% | – |
| Cost of Goods Sold | $92 | $80 | $103 | $58 |
| Gross Profit | $139 | $61 | $119 | $137 |
| % Margin | 60.3% | 43.1% | 53.7% | 70.1% |
| R&D Expenses | $14 | $13 | $15 | $9 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $39 | $44 | $53 | $61 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $11 | $3 | $2 | $76 |
| Operating Expenses | $63 | $59 | $70 | $146 |
| Operating Income | $77 | $2 | $50 | -$10 |
| % Margin | 33.1% | 1.1% | 22.5% | -4.9% |
| Other Income/Exp. Net | -$19 | -$18 | $43 | -$18 |
| Pre-Tax Income | $58 | -$17 | $93 | -$28 |
| Tax Expense | $6 | -$5 | $25 | $4 |
| Net Income | $51 | -$12 | $68 | -$31 |
| % Margin | 22.2% | -8.5% | 30.6% | -16.1% |
| EPS | 0.96 | -0.22 | 1.25 | -0.59 |
| % Growth | 536.4% | -117.6% | 311.9% | – |
| EPS Diluted | 0.91 | -0.22 | 1.19 | -0.59 |
| Weighted Avg Shares Out | 53 | 54 | 54 | 54 |
| Weighted Avg Shares Out Dil | 57 | 54 | 57 | 54 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $15 | $15 | $15 | $15 |
| Depreciation & Amortization | $23 | $23 | $25 | $25 |
| EBITDA | $96 | $24 | $75 | $21 |
| % Margin | 41.6% | 16.7% | 33.8% | 10.8% |